Lea’s Shield Clinical Investigator Warned For Improper Informed Consent
This article was originally published in The Gray Sheet
Informed consent and records violations by clinical investigator Mitchell Creinin, MD, University of Pittsburgh, during the pivotal trial for Yama, Inc.'s Lea's Shield were significant enough to draw a warning letter, but did not hinder approval of the PMA
You may also be interested in...
Yama, Inc. is positioning its Lea's Shield reusable barrier contraceptive device as "more convenient" than traditional diaphragms
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.